Investigational H7N1 vaccine GSK2789869A

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 1

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

CompletedNCT01934127

GlaxoSmithKlineInfluenza

Start: 2013-08-26End: 2014-10-20Updated: 2017-05-08

Phase 2

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

CompletedNCT01949090

GlaxoSmithKlineInfluenza

Start: 2013-09-25End: 2014-10-23Updated: 2017-11-17

Related Papers

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial

Vaccine2017-03-1415 citations

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial

Vaccine2017-02-0812 citations